the way the nucleotide cycles, the nature of the binding pockets that led us to believe that targeting other mutants is possible,” Mirati’s Christensen says. But, he cautions, KRAS G12D still ...

The company has returned to Redx Pharma’s well, this time paying $10 million upfront for a KRAS program that includes the much-hyped G12D space. Initially Jazz and Redx will collaborate to ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib ...

QTX3034 and QTX3046 tightly bind to GDP-bound G12D-mutated KRAS and inhibit GDP-to-GTP nucleotide exchange, which prevents KRAS activation and subsequent RAF binding. QTX3046 also potently binds to ...

“This trial is the first time we’ve ever seen this kind of benefit in treating non-small cell lung cancers caused by KRAS-G12D,” Dr. Arbour says. “What we saw in these patients is dramatically ...

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

The study showed that KRAS G12D inhibition induced expression of the Fas pathway, reversed early tumor growth, increased CD8+ T cell infiltration, decreased myeloid infiltration and reprogrammed ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application of VS-7375, its oral KRAS G12D inhibitor. An oral KRAS G12D inhibitor ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

Verastem Oncology has announced the dosing of the first patient with GFH375/VS-7375, a potent and selective oral KRAS G12D (ON/OFF) inhibitor, as part of a Phase I/II clinical trial in China.